WO2020020288A1 - 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 - Google Patents
作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 Download PDFInfo
- Publication number
- WO2020020288A1 WO2020020288A1 PCT/CN2019/097692 CN2019097692W WO2020020288A1 WO 2020020288 A1 WO2020020288 A1 WO 2020020288A1 CN 2019097692 W CN2019097692 W CN 2019097692W WO 2020020288 A1 WO2020020288 A1 WO 2020020288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- amino
- pharmaceutically acceptable
- acceptable salt
- formula
- Prior art date
Links
- 0 C*c1ccccc1 Chemical compound C*c1ccccc1 0.000 description 7
- WXGGBVVJJBPKED-VOTSOKGWSA-N C/C=C/c(cc1C)cc(C)c1Oc(ccc(N=S(C)(C)=O)c1)c1Br Chemical compound C/C=C/c(cc1C)cc(C)c1Oc(ccc(N=S(C)(C)=O)c1)c1Br WXGGBVVJJBPKED-VOTSOKGWSA-N 0.000 description 1
- PGHUCOLOCDNUMQ-UHFFFAOYSA-N C=S1(CCCC1)=O Chemical compound C=S1(CCCC1)=O PGHUCOLOCDNUMQ-UHFFFAOYSA-N 0.000 description 1
- USTPKRFGVDEVCL-UHFFFAOYSA-N C=S1(CCCCC1)=O Chemical compound C=S1(CCCCC1)=O USTPKRFGVDEVCL-UHFFFAOYSA-N 0.000 description 1
- IKYBXWDFXORLBL-UHFFFAOYSA-N CC(C(C=C1)=O)=CN1c(ccc(N=S(C)(C)=O)c1)c1C(c1c2[nH]cc1)=CN(C)C2=O Chemical compound CC(C(C=C1)=O)=CN1c(ccc(N=S(C)(C)=O)c1)c1C(c1c2[nH]cc1)=CN(C)C2=O IKYBXWDFXORLBL-UHFFFAOYSA-N 0.000 description 1
- GUUYWIORVKASJW-UHFFFAOYSA-N CC(C)(C)C1COCC1 Chemical compound CC(C)(C)C1COCC1 GUUYWIORVKASJW-UHFFFAOYSA-N 0.000 description 1
- UXTMRFPRDCYGFX-UHFFFAOYSA-N CC(C)(C)OC(N(c(ccc(F)c1)c1F)c(c(Br)c1)ccc1N=S(C)(C)=O)=O Chemical compound CC(C)(C)OC(N(c(ccc(F)c1)c1F)c(c(Br)c1)ccc1N=S(C)(C)=O)=O UXTMRFPRDCYGFX-UHFFFAOYSA-N 0.000 description 1
- HDOCRWHBYOGXQP-VQHVLOKHSA-N CCc(cc(cc1Br)N=S(C)(C)=O)c1Oc1c(C)cc(/C=C/C)cc1C Chemical compound CCc(cc(cc1Br)N=S(C)(C)=O)c1Oc1c(C)cc(/C=C/C)cc1C HDOCRWHBYOGXQP-VQHVLOKHSA-N 0.000 description 1
- UTLGQYLRKKKDMP-UHFFFAOYSA-N C[BrH]c(cc(cc1)[N+]([O-])=O)c1Oc(c(F)c1)ccc1F Chemical compound C[BrH]c(cc(cc1)[N+]([O-])=O)c1Oc(c(F)c1)ccc1F UTLGQYLRKKKDMP-UHFFFAOYSA-N 0.000 description 1
- KUQQONVKIURIQU-UHFFFAOYSA-N Cc(c(F)c1)ccc1C#N Chemical compound Cc(c(F)c1)ccc1C#N KUQQONVKIURIQU-UHFFFAOYSA-N 0.000 description 1
- RPDWLJUICYERPJ-UHFFFAOYSA-N Cc(c([F]C)c1)ccc1F Chemical compound Cc(c([F]C)c1)ccc1F RPDWLJUICYERPJ-UHFFFAOYSA-N 0.000 description 1
- YYDNBUBMBZRNQQ-UHFFFAOYSA-N Cc(cc1)ccc1S(C)(=O)=O Chemical compound Cc(cc1)ccc1S(C)(=O)=O YYDNBUBMBZRNQQ-UHFFFAOYSA-N 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N Cc1c(C)nccc1 Chemical compound Cc1c(C)nccc1 HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- NVLHGZIXTRYOKT-UHFFFAOYSA-N Cc1cccc(Cl)c1C Chemical compound Cc1cccc(Cl)c1C NVLHGZIXTRYOKT-UHFFFAOYSA-N 0.000 description 1
- PXSXEXXLNMKGBT-UHFFFAOYSA-N Nc(cc1)cc(Br)c1Oc(ccc(F)c1)c1F Chemical compound Nc(cc1)cc(Br)c1Oc(ccc(F)c1)c1F PXSXEXXLNMKGBT-UHFFFAOYSA-N 0.000 description 1
- BBMQNTUUBCWXLI-UHFFFAOYSA-N [O-][N+](c(cc1)cc(Br)c1OCC1COCC1)=O Chemical compound [O-][N+](c(cc1)cc(Br)c1OCC1COCC1)=O BBMQNTUUBCWXLI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present application relates to iminosulfone compounds and pharmaceutically acceptable salts thereof as inhibitors of bromodomain proteins.
- the application also relates to a method for preparing the compound, a pharmaceutical composition, and a medicinal use thereof.
- the epigenetic regulation of transcribed genes plays an important role in the development of tumors, inflammation and metabolic diseases.
- the acetylation of nucleoside histone lysine N-terminal residues is particularly important for the regulation of genetic epigenetic genes. While histone acetylation is usually most related to the activation of gene transcription, recognition of histone lysine acetylation is a key step in histone acetylation involved in epigenetic regulation.
- Bromodomains are a class of conserved protein domains that specifically recognize acetylated lysine (KAc) in histones, and promote chromatin remodeling and transcription factors by binding to acetylated lysine Other related proteins are enriched in specific gene transcription sites and change the activity of RNA II polymerase, thus cooperating to complete gene expression regulation (Filippakopoulos P, Picaud S, Mangos M, et al. Cell, 2012, 149 (1): 214-231 ).
- BET Breast and Extra Terminal proteins include two interlinked bromodomain centers and an outer terminal domain. They are divided into four proteins: Brd2, Brd3, Brd4, and BrdT according to different amino acid sequences.
- BET is a type of transcriptional regulatory protein that plays a very important role in regulating gene expression through interaction with chromatin. BET protein has two-way regulatory functions for co-activation or co-suppression of intracellular reticular signaling pathways, such as insulin transcription, adipogenesis in lipid tissue, differentiation of hematopoietic systems, etc. (Belkina A, Denis G, V, Nature Reviews Cancer, 2012, 12 (7): 465-477).
- BET protein has increasingly become one of the important targets in the field of epigenetics, which has attracted great attention from major pharmaceutical companies and scientific research institutions.
- This application takes the BET protein as a target, and develops a new type of iminosulfone small molecule compound, which is used to treat tumors, inflammation, and metabolic diseases.
- R 1 is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is optionally substituted with one or more halogens;
- Y is selected from O, S or NR Y , said R Y is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is Optionally substituted with one or more halogens;
- X 1 is selected from N or CR X1 , and R X1 is selected from H, C 1 -C 6 alkyl, halogen, or C 1 -C 6 haloalkyl;
- X 2 is selected from N or CR X2
- X 3 is selected from N or CR X3
- the R X2 and R X3 each independently selected from H, halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl, -C (O) OR a , -C (O) NR b R c , -C (O) R d , -S (O) 2 R e or -S (O) 2 NR b R c , the C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl is optionally substituted with one or more halogen, hydroxyl, amino, nitro or cyano;
- Z 1 is selected from N or CR Z1
- Z 2 is selected from N or CR Z2
- Z 3 is selected from N or CR Z3
- R Z1 , R Z2 , and R Z3 are each independently selected from H, C 1 -C 6 Alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, cyano or nitro, said C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 Alkynyl is optionally substituted with one or more halogen, hydroxyl, amino, nitro or cyano;
- R 2 and R 3 are each independently selected from halogen, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1- C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino, the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy Optionally substituted with one or more halogen, hydroxy, amino, nitro or cyano; C 1 -C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino;
- R 2 and R 3 are connected and form a 3-membered to 8-membered heterocycloalkyl group with the adjacent S atom, and the 3-membered to 8-membered heterocycloalkyl group except for the S atom in which R 2 and R 3 are connected together
- it optionally contains 1 to 3 heteroatoms selected from N, O or S
- the ring carbon atom of the 3- to 8-membered heterocycloalkyl is optionally substituted by one or more halogen, hydroxyl, amino, Nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or (C 1 -C 6 alkyl) 2 amino Substituted or substituted with one or more oxo groups;
- L is selected from a single bond, -O-, -NH-,-(C 1 -C 3 alkyl) -O-,-(C 1 -C 3 alkyl) -NH- or -C 1 -C 3 alkyl -;
- R 4 is selected from C 6 -C 10 aryl, C 3 -C 10 cycloalkenyl, C 3 -C 10 cycloalkyl, 3- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkenyl, or 3 3- to 10-membered heterocycloalkyl, the 3- to 10-membered heteroaryl, 3- to 10-membered heteroalkenyl or 3- to 10-membered heterocycloalkyl each independently contains 1 to 3 selected from N , O or S hetero atom; said R 4 is optionally substituted by one or more halogen, hydroxyl, amino, nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, (C 1 -C 6 alkyl) 2 amino, -C (O) OR a , -C (O) NR b R c , -C (O)
- R a, R b, R c , R d and R e are each independently selected from H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- R 1 is selected from H or C 1 -C 3 alkyl, and the C 1 -C 3 alkyl is optionally substituted with one or more F, Cl or Br.
- R 1 is selected from H, methyl, ethyl, propyl, or trifluoromethyl.
- the Y is selected from NR Y
- the R Y is selected from H, C 1 -C 3 alkyl
- the C 1 -C 3 alkyl is optionally substituted by one or more F, Cl or Br substituted.
- the Y is selected from NH or N (CH 3 ).
- the X 1 is selected from CR X1
- the R X1 is selected from H, C 1 -C 4 alkyl, F, Cl, Br or F, Cl or Br-substituted C 1 -C 4 alkyl.
- X 1 is selected from CH.
- the X 2 is selected from CR X2, the R X2 is selected from H, -C (O) OR a or -C (O) NR b R c .
- the X 2 is selected from CR X2, the R X2 is selected from H, -C (O) OH, -C (O) OCH 3, -C (O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O) N (C 2 H 5 ) 2 or -C (O) NHCH 2 CF 3 .
- the X 3 is selected from CR X3, R X3 is selected from H or a C 1 -C 4 alkyl, said C 1 -C 4 alkyl is optionally substituted with one or more F, Cl, Br, hydroxyl, amino, nitro or cyano substituted.
- the X 3 is selected from CH.
- the Z 1 is selected from N or CR Z1
- the R Z1 is selected from H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkyne Group, halogen, cyano or nitro, said C 1 -C 4 alkyl, C 2 -C 4 alkenyl or C 2 -C 4 alkynyl is optionally substituted by one or more halogen, hydroxyl, amino, nitrate Or cyano.
- Z 1 is selected from N or CH.
- Z 1 is selected from N.
- the Z 2 is selected from CR Z2
- the R Z2 is selected from H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl group, Halogen, cyano or nitro, said C 1 -C 4 alkyl, C 2 -C 4 alkenyl or C 2 -C 4 alkynyl optionally by one or more F, Cl, Br, hydroxyl, amino , Nitro or cyano.
- the Z 2 is selected from CH.
- the Z 3 is selected from N or CR Z3
- the R Z3 is selected from H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkyne Group, halogen, cyano or nitro
- the C 1 -C 4 alkyl, C 2 -C 4 alkenyl or C 2 -C 4 alkynyl is optionally substituted by one or more F, Cl, Br, hydroxy , Amino, nitro or cyano.
- the Z 3 is selected from N or CH.
- the Z 3 is selected from N.
- the R 2 and R 3 are each independently selected from C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 Alkoxy, C 1 -C 4 alkylamino or (C 1 -C 4 alkyl) 2 amino, the C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino or (C 1 -C 4 alkyl) 2 amino optionally by one or more F, Cl, Br, hydroxyl, amino, nitro or cyano Radical substitution; or R 2 and R 3 are connected and form a 4-membered to 6-membered heterocycloalkyl group with the adjacent S atom, and the 4-membered to 6-membered heterocycloalkyl group is commonly connected except R 2 and R 3 In addition to the S atom
- the L is selected from a single bond, -O-, -NH-, or-(C 1 -C 3 alkyl) -O-.
- the R 4 is selected from phenyl, naphthyl, piperidinyl, pyridyl, imidazolyl, pyrazolyl, pyrazinyl, piperazinyl, thienyl, furyl, and thiazole Group, isothiazolyl, oxazolyl, isoxazolyl, 1,4-dihydropyridyl or tetrahydrofuranyl; said R 4 is optionally substituted by one or more F, Cl, Br, cyano, methyl , ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O) OC 2 H 5,
- the R 4 is selected from R 4 is optionally substituted by one or more of F, Cl, Br, cyano, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O ) N (C 2 H 5 ) 2 , Acetyl, -S (O) 2 CH 3 , -S (O) 2 C 2 H 5 , -NHS (O) 2 CH 3 , -S (O) 2
- the R 4 is selected from
- R 1 , R Y , R X1 , R X2 , R X3 , R Z1 , R Z2 , Z 3 , R 2 , R 3 , L and R 4 are as defined above.
- R 1 is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is optionally substituted with one or more halogens;
- R Y is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is optionally substituted with one or more halogens;
- R X1 is selected from H, C 1 -C 6 alkyl, halogen or C 1 -C 6 haloalkyl;
- R X2 is selected from H, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C (O) OR a , -C (O) NR b R c , -C (O) R d, -S (O) 2 R e , or -S (O) 2 NR b R c, said C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl group optionally substituted with one or more halogen, hydroxy, amino, nitro or cyano;
- R 2 and R 3 are each independently selected from halogen, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1- C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino, the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy Optionally substituted with one or more halogen, hydroxy, amino, nitro or cyano; C 1 -C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino;
- R 2 and R 3 are connected and form a 3-membered to 8-membered heterocycloalkyl group with the adjacent S atom, and the 3-membered to 8-membered heterocycloalkyl group except for the S atom in which R 2 and R 3 are connected together
- it optionally contains 1 to 3 heteroatoms selected from N, O or S
- the ring carbon atom of the 3- to 8-membered heterocycloalkyl is optionally substituted by one or more halogen, hydroxyl, amino, Nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or (C 1 -C 6 alkyl) 2 amino Substituted or substituted with one or more oxo groups;
- L is selected from a single bond, -O-, -NH-,-(C 1 -C 3 alkyl) -O-,-(C 1 -C 3 alkyl) -NH- or -C 1 -C 3 alkyl -;
- R 4 is selected from C 6 -C 10 aryl, C 3 -C 10 cycloalkenyl, C 3 -C 10 cycloalkyl, 3- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkenyl, or 3 3- to 10-membered heterocycloalkyl, the 3- to 10-membered heteroaryl, 3- to 10-membered heteroalkenyl or 3- to 10-membered heterocycloalkyl each independently contains 1 to 3 selected from N , O or S hetero atom; said R 4 is optionally substituted by one or more halogen, hydroxyl, amino, nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, (C 1 -C 6 alkyl) 2 amino, -C (O) OR a , -C (O) NR b R c , -C (O)
- R a, R b, R c , R d and R e are each independently selected from H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- the R 1 is selected from H or C 1 -C 3 alkyl, and the C 1 -C 3 alkyl is It is optionally substituted with one or more F, Cl or Br.
- R 1 is selected from H, methyl, ethyl, propyl, or trifluoromethyl.
- the R Y is selected from H, C 1 -C 3 alkyl, and the C 1 -C 3 alkyl is It is optionally substituted with one or more F, Cl or Br.
- the R Y is selected from H.
- the R X1 is selected from the group consisting of H, C 1 -C 4 alkyl, F, Cl, Br, or F, Cl. Or Br substituted C 1 -C 4 alkyl.
- the R X1 is selected from H.
- the R X2 is selected from the group consisting of H, -C (O) OH, -C (O) OCH 3 , -C ( O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O) N (C 2 H 5 ) 2 or -C (O) NHCH 2 CF 3 .
- the R X2 is selected from H.
- each of R 2 and R 3 is independently selected from C 1 -C 4 alkyl, C 2 -C 4 ene Alkyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, or (C 1 -C 4 alkyl) 2 amino, the C 1 -C 4 alkyl, C 2- C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, or (C 1 -C 4 alkyl) 2 amino is optionally substituted by one or more F, Cl, Br, hydroxyl, amino, nitro or cyano; or R 2 and R 3 are connected and form a 4-membered to 6-membered heterocycloalkyl group with the adjacent S atom.
- the 6-membered heterocycloalkyl group optionally contains 1 to 3 heteroatoms selected from N, O, or S in addition to the S atom in which R 2 and R 3 are commonly connected; Ring carbon atoms are optionally substituted by one or more F, Cl, Br, hydroxyl, amino, nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy Group, C 1 -C 4 alkylamino or (C 1 -C 4 alkyl) 2 amino, or substituted with one or more oxo groups.
- the L is selected from a single bond, -O-, -NH-, or-(C 1 -C 3 alkyl) -O-.
- the L is selected from -O-.
- R 4 is selected from phenyl, naphthyl, piperidinyl, pyridyl, imidazolyl, pyrazolyl, Pyrazinyl, piperazinyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, 1,4-dihydropyridyl or tetrahydrofuranyl; said R 4 is optionally One or more of F, Cl, Br, cyano, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O)
- R 4 is selected from R 4 is optionally substituted by one or more of F, Cl, Br, cyano, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O ) N (C 2 H 5 ) 2 , Acetyl, -S (O) 2 CH 3 , -S (O) 2 C 2 H 5 ,
- R 4 is selected from
- R 1 is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is optionally substituted with one or more halogens;
- R Y is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is optionally substituted with one or more halogens;
- R X1 is selected from H, C 1 -C 6 alkyl, halogen or C 1 -C 6 haloalkyl;
- R X2 is selected from H, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C (O) OR a , -C (O) NR b R c , -C (O) R d, -S (O) 2 R e , or -S (O) 2 NR b R c, said C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl group optionally substituted with one or more halogen, hydroxy, amino, nitro or cyano;
- R 2 and R 3 are each independently selected from halogen, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1- C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino, the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy Optionally substituted with one or more halogen, hydroxy, amino, nitro or cyano; C 1 -C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino;
- R 2 and R 3 are connected and form a 3-membered to 8-membered heterocycloalkyl group with the adjacent S atom, and the 3-membered to 8-membered heterocycloalkyl group except for the S atom in which R 2 and R 3 are connected together
- it optionally contains 1 to 3 heteroatoms selected from N, O or S
- the ring carbon atom of the 3- to 8-membered heterocycloalkyl is optionally substituted by one or more halogen, hydroxyl, amino, Nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or (C 1 -C 6 alkyl) 2 amino Substituted or substituted with one or more oxo groups;
- L is selected from a single bond, -O-, -NH-,-(C 1 -C 3 alkyl) -O-,-(C 1 -C 3 alkyl) -NH- or -C 1 -C 3 alkyl -;
- R 4 is selected from C 6 -C 10 aryl, C 3 -C 10 cycloalkenyl, C 3 -C 10 cycloalkyl, 3- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkenyl, or 3 3- to 10-membered heterocycloalkyl, the 3- to 10-membered heteroaryl, 3- to 10-membered heteroalkenyl or 3- to 10-membered heterocycloalkyl each independently contains 1 to 3 selected from N , O or S hetero atom; said R 4 is optionally substituted by one or more halogen, hydroxyl, amino, nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, (C 1 -C 6 alkyl) 2 amino, -C (O) OR a , -C (O) NR b R c , -C (O)
- R a, R b, R c , R d and R e are each independently selected from H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- R 1 is selected from H or C 1 -C 3 alkyl, and C 1 -C 3 alkyl is either It is optionally substituted with one or more F, Cl or Br.
- the R 1 is selected from H, methyl, ethyl, propyl, or trifluoromethyl.
- the R Y is selected from H, C 1 -C 3 alkyl, and the C 1 -C 3 alkyl is It is optionally substituted with one or more F, Cl or Br.
- the R Y is selected from H.
- the R X1 is selected from the group consisting of H, C 1 -C 4 alkyl, F, Cl, Br, or F, Cl. Or Br substituted C 1 -C 4 alkyl.
- the R X1 is selected from H.
- the R X2 is selected from the group consisting of H, -C (O) OH, -C (O) OCH 3 , -C ( O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O) N (C 2 H 5 ) 2 or -C (O) NHCH 2 CF 3 .
- the R X2 is selected from H.
- each of R 2 and R 3 is independently selected from C 1 -C 4 alkyl, C 2 -C 4 ene Alkyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, or (C 1 -C 4 alkyl) 2 amino, the C 1 -C 4 alkyl, C 2- C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, or (C 1 -C 4 alkyl) 2 amino is optionally substituted by one or more F, Cl, Br, hydroxyl, amino, nitro or cyano; or R 2 and R 3 are connected and form a 4-membered to 6-membered heterocycloalkyl group with the adjacent S atom.
- the 6-membered heterocycloalkyl group optionally contains 1 to 3 heteroatoms selected from N, O, or S in addition to the S atom in which R 2 and R 3 are commonly connected; Ring carbon atoms are optionally substituted by one or more F, Cl, Br, hydroxyl, amino, nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy Group, C 1 -C 4 alkylamino or (C 1 -C 4 alkyl) 2 amino, or substituted with one or more oxo groups.
- the L is selected from a single bond, -O-, -NH-, or-(C 1 -C 3 alkyl) -O-.
- the L is selected from -O-.
- R 4 is selected from the group consisting of phenyl, naphthyl, piperidinyl, pyridyl, imidazolyl, pyrazolyl, Pyrazinyl, piperazinyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, 1,4-dihydropyridyl or tetrahydrofuryl; said R 4 is optionally One or more of F, Cl, Br, cyano, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O) OH, -C (O) OCH 3, -C (
- R 4 is selected from R 4 is optionally substituted by one or more of F, Cl, Br, cyano, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O ) N (C 2 H 5 ) 2 , Acetyl, -S (O) 2 CH 3 , -S (O) 2 C 2 H 5 ,
- R 4 is selected from
- R 1 is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is optionally substituted with one or more halogens;
- R Y is selected from H, C 1 -C 3 alkyl or C 1 -C 3 acyl, said C 1 -C 3 alkyl or C 1 -C 3 acyl is optionally substituted with one or more halogens;
- R X1 is selected from H, C 1 -C 6 alkyl, halogen or C 1 -C 6 haloalkyl;
- R X2 is selected from H, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C (O) OR a , -C (O) NR b R c , -C (O) R d, -S (O) 2 R e , or -S (O) 2 NR b R c, said C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl group optionally substituted with one or more halogen, hydroxy, amino, nitro or cyano;
- R 2 and R 3 are each independently selected from halogen, hydroxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1- C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino, the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy Optionally substituted with one or more halogen, hydroxy, amino, nitro or cyano; C 1 -C 6 alkylamino or (C 1 -C 6 alkyl) 2 amino;
- R 2 and R 3 are connected and form a 3-membered to 8-membered heterocycloalkyl group with the adjacent S atom, and the 3-membered to 8-membered heterocycloalkyl group except for the S atom in which R 2 and R 3 are connected together
- it optionally contains 1 to 3 heteroatoms selected from N, O or S
- the ring carbon atom of the 3- to 8-membered heterocycloalkyl is optionally substituted by one or more halogen, hydroxyl, amino, Nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or (C 1 -C 6 alkyl) 2 amino Substituted or substituted with one or more oxo groups;
- L is selected from a single bond, -O-, -NH-,-(C 1 -C 3 alkyl) -O-,-(C 1 -C 3 alkyl) -NH- or -C 1 -C 3 alkyl -;
- R 4 is selected from C 6 -C 10 aryl, C 3 -C 10 cycloalkenyl, C 3 -C 10 cycloalkyl, 3- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkenyl, or 3 3- to 10-membered heterocycloalkyl, the 3- to 10-membered heteroaryl, 3- to 10-membered heteroalkenyl or 3- to 10-membered heterocycloalkyl each independently contains 1 to 3 selected from N , O or S hetero atom; said R 4 is optionally substituted by one or more halogen, hydroxyl, amino, nitro, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, (C 1 -C 6 alkyl) 2 amino, -C (O) OR a , -C (O) NR b R c , -C (O)
- R a, R b, R c , R d and R e are each independently selected from H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- R 1 is selected from H or C 1 -C 3 alkyl, and C 1 -C 3 alkyl is either It is optionally substituted with one or more F, Cl or Br.
- R 1 is selected from H, methyl, ethyl, propyl, or trifluoromethyl.
- the R Y is selected from H, C 1 -C 3 alkyl, and the C 1 -C 3 alkyl is It is optionally substituted with one or more F, Cl or Br.
- the R Y is selected from H.
- the R X1 is selected from H, C 1 -C 4 alkyl, F, Cl, Br, or F, Cl. Or Br substituted C 1 -C 4 alkyl.
- the R X1 is selected from H.
- the R X2 is selected from the group consisting of H, -C (O) OH, -C (O) OCH 3 , -C ( O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O) N (C 2 H 5 ) 2 or -C (O) NHCH 2 CF 3 .
- the R X2 is selected from H, -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 or -C (O) N (C 2 H 5 ) 2 .
- each of R 2 and R 3 is independently selected from C 1 -C 4 alkyl, C 2 -C 4 ene Alkyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, or (C 1 -C 4 alkyl) 2 amino, the C 1 -C 4 alkyl, C 2- C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, or (C 1 -C 4 alkyl) 2 amino is optionally substituted by one or more F, Cl, Br, hydroxyl, amino, nitro or cyano; or R 2 and R 3 are connected and form a 4-membered to 6-membered heterocycloalkyl group with the adjacent S atom.
- the 6-membered heterocycloalkyl group optionally contains 1 to 3 heteroatoms selected from N, O, or S in addition to the S atom in which R 2 and R 3 are commonly connected; Ring carbon atoms are optionally substituted by one or more F, Cl, Br, hydroxyl, amino, nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy Group, C 1 -C 4 alkylamino or (C 1 -C 4 alkyl) 2 amino, or substituted with one or more oxo groups.
- the L is selected from a single bond, -O-, -NH-, or-(C 1 -C 3 alkyl) -O-.
- the L is selected from -O-.
- R 4 is selected from phenyl, naphthyl, piperidinyl, pyridyl, imidazolyl, pyrazolyl, Pyrazinyl, piperazinyl, thienyl, furyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, 1,4-dihydropyridyl or tetrahydrofuranyl; said R 4 is optionally One or more of F, Cl, Br, cyano, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O)
- the R 4 is selected from R 4 is optionally substituted by one or more of F, Cl, Br, cyano, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, (methyl) 2 amino, (ethyl) 2 amino, (propyl) amino-2, -C (O) OH, -C (O) OCH 3, -C (O) OC 2 H 5 , -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHC 2 H 5 , -C (O) N (CH 3 ) 2 , -C (O ) N (C 2 H 5 ) 2 , Acetyl, -S (O) 2 CH 3 , -S (O) 2 C 2 H
- the R 4 is selected from
- the present application relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the present application or a pharmaceutically acceptable salt thereof.
- the pharmaceutical compositions of the present application further include a pharmaceutically acceptable excipient.
- the present application relates to a method for treating a mammal-mediated disease, including administering a therapeutically effective amount of the applied compound or a pharmaceutically acceptable salt thereof to a mammal (preferably a human) in need of such treatment, or Its pharmaceutical composition.
- the present application relates to the use of a compound of the present application, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for treating a disease mediated by a BET protein.
- the disease mediated by the BET protein is selected from cancer.
- the cancer is selected from solid tumors or hematological tumors. More preferably, the solid tumor is selected from breast cancer or prostate cancer. More preferably, the hematological tumor is selected from the group consisting of acute myeloid leukemia, multiple myeloma, or diffuse large B-cell lymphoma.
- substituted means that any one or more hydrogen atoms on a specific atom are substituted with a substituent, as long as the valence of the specific atom is normal and the substituted compound is stable.
- it means that two hydrogen atoms are substituted, and oxo does not occur on the aromatic group.
- an ethyl group is "optionally” substituted with a halogen, meaning that the ethyl group may be unsubstituted (CH 2 CH 3 ), mono-substituted (such as CH 2 CH 2 F), poly-substituted (such as CHFCH 2 F, CH 2 CHF 2 etc.) or completely substituted (CF 2 CF 3 ).
- C mn in this document means that the part has an integer number of carbon atoms in a given range.
- C 1-6 means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.
- any variable such as R
- its definition in each case is independent. So, for example, if one group is replaced by 2 Rs, each R has independent options.
- halogen refers to fluorine, chlorine, bromine and iodine.
- hydroxy refers to the -OH group.
- cyano refers to the -CN group.
- amino refers to the -NH 2 group.
- nitro means a -NO 2 group.
- alkyl refers to a hydrocarbon group of the formula C n H 2n +.
- the alkyl group may be linear or branched.
- C 1 - 6 alkyl refers to (e.g., methyl, ethyl, n-propyl, isopropyl, alkyl containing 1 to 6 carbon atoms, n-butyl, isobutyl, sec-butyl, Tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.).
- the alkyl portion (ie, alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl, and alkylthio has the same definitions as described above.
- alkoxy refers to -O-alkyl
- alkylamino refers to -NH-alkyl
- dialkylamino refers to -N (alkyl) 2 .
- alkenyl refers to a linear or branched unsaturated aliphatic hydrocarbon group having at least one double bond consisting of a carbon atom and a hydrogen atom.
- alkenyl include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, and the like.
- alkynyl refers to a linear or branched unsaturated aliphatic hydrocarbon group having at least one triple bond consisting of a carbon atom and a hydrogen atom.
- alkynyl include, but are not limited to, ethynyl (-C ⁇ CH), 1-propynyl (-C ⁇ C-CH 3 ), 2-propynyl (-CH 2 -C ⁇ CH), 1,3-butadiynyl (-C ⁇ CC ⁇ CH) and the like.
- cycloalkyl refers to a carbocyclic ring that is fully saturated and can exist as a monocyclic, bridged, or spiro ring. Unless otherwise indicated, the carbocyclic ring is usually a 3 to 10 membered ring.
- Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo [2.2.1] heptyl), bicyclo [2.2.2] octyl, adamantine Alkyl, etc.
- cycloalkenyl refers to a non-aromatic carbocyclic ring that is not fully saturated and may exist as a single ring, bridged ring, or spiro ring. Unless otherwise indicated, the carbocyclic ring is usually a 5- to 8-membered ring.
- Non-limiting examples of cycloalkenyl include, but are not limited to, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, and the like.
- heterocycloalkenyl refers to a cycloalkenyl group as described above containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, and / or nitrogen.
- heterocycloalkyl refers to a cyclic group that is fully saturated and can exist as a monocyclic, bridged or spiro ring. Unless otherwise indicated, the heterocyclic ring is generally a 3 to 7 membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, and / or nitrogen. Examples of 3-membered heterocycloalkyl include, but are not limited to, ethylene oxide, epithioethane, and cycloazinyl.
- Non-limiting examples of 4-membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetane
- Examples of cyclic groups, thiobutane groups, and 5-membered heterocycloalkyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolyl, and thiazolidine
- Examples of imidazolyl, tetrahydropyrazolyl, and 6-membered heterocycloalkyl include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothyranyl, morpholinyl, piperazinyl, 1, Examples of 4-thiaoxaalkyl, 1,4-dioxane, thiomorpholinyl, 1,3-dithia
- aryl refers to a full-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated pi-electron system.
- an aryl group may have 6-20 carbon atoms, 6-14 carbon atoms, or 6-12 carbon atoms.
- Non-limiting examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, 1,2,3,4-tetrahydronaphthalene, and the like.
- heteroaryl refers to a monocyclic or fused polycyclic ring system containing at least one ring atom selected from N, O, and S, the remaining ring atoms being C, and having at least one aromatic ring.
- Preferred heteroaryl groups have a single 4- to 8-membered ring, especially a 5- to 8-membered ring, or multiple fused rings containing 6 to 14, especially 6 to 10 ring atoms.
- heteroaryl include, but are not limited to, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl , Tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl, and the like.
- treating means administering a compound or formulation described herein to prevent, ameliorate or eliminate a disease or one or more symptoms associated with the disease, and includes:
- terapéuticaally effective amount means (i) treats or prevents a specific disease, condition or disorder, (ii) reduces, improves or eliminates one or more symptoms of a specific disease, condition or disorder, or (iii) prevents or delays
- the amount of the compound of the present application that constitutes a “therapeutically effective amount” varies depending on the compound, the state of the disease and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art based on Determined by its own knowledge and this disclosure.
- pharmaceutically acceptable refers to those compounds, materials, compositions, and / or dosage forms that are within the scope of sound medical judgment and are suitable for use in contact with human and animal tissues without More toxic, irritating, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.
- salts for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like can be mentioned. .
- composition refers to a mixture of one or more compounds of the present application or a salt thereof and a pharmaceutically acceptable excipient.
- the purpose of a pharmaceutical composition is to facilitate administration of a compound of the present application to an organism.
- pharmaceutically acceptable excipients refers to those excipients that have no significant stimulating effect on the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
- tautomers or “tautomeric forms” refers to structural isomers of different energies that can interconvert via a low energy barrier.
- proton tautomers also known as proton transfer tautomers
- proton transfer tautomers include interconversions via migration of protons, such as keto-enol and imine-enamine isomerizations.
- a specific example of a proton tautomer is an imidazole moiety, in which a proton can migrate between two ring nitrogens.
- Valence tautomers include interconversions through recombination of some bonding electrons.
- This application also includes isotopically-labeled compounds of the present application that are the same as those described herein, but with one or more atoms replaced by an atomic weight or mass number different from the atomic weight or mass number usually found in nature.
- isotopes that can be incorporated into the compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I, and 36 Cl.
- isotopically labeled compounds of the present application can be used in compound and / or substrate tissue distribution analysis. Tritiated (ie 3 H) and carbon-14 (ie 14 C) isotopes are particularly preferred due to their ease of preparation and detectability.
- Positron emission isotopes such as 15 O, 13 N, 11 C, and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy.
- Isotopically labeled compounds of the present application can generally be prepared by the following procedures similar to those disclosed in the schemes and / or examples below by replacing isotopically labeled reagents with isotopically labeled reagents.
- the compounds of the present application may be asymmetric, for example, having one or more stereoisomers. Unless otherwise stated, all stereoisomers are included, such as enantiomers and diastereomers.
- the compounds containing asymmetric carbon atoms of the present application can be isolated in optically active pure form or in racemic form. Optically active pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
- the pharmaceutical composition of the present application can be prepared by combining the compound of the present application with a suitable pharmaceutically acceptable excipient, for example, it can be formulated into a solid, semi-solid, liquid or gaseous preparation, such as a tablet, pill, capsule, powder , Granules, creams, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols.
- a suitable pharmaceutically acceptable excipient for example, it can be formulated into a solid, semi-solid, liquid or gaseous preparation, such as a tablet, pill, capsule, powder , Granules, creams, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols.
- Typical routes for administering a compound of this application or a pharmaceutically acceptable salt or pharmaceutical composition thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, Intramuscular, subcutaneous, intravenous.
- the pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as a conventional mixing method, a dissolution method, a granulation method, a sugar-coated pills method, a grinding method, an emulsification method, a freeze-drying method, and the like.
- the pharmaceutical composition is in an oral form.
- the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, dragees, dragees, capsules, liquids, gels, slurries, suspensions, and the like for oral administration to patients.
- Solid oral compositions can be prepared by conventional mixing, filling or tabletting methods. For example, it can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into granules to obtain tablets. Or the core of a sugar coating agent. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, glidants, sweeteners, or flavoring agents.
- compositions are also suitable for parenteral administration, such as sterile unit solutions, suspensions or lyophilized products in suitable unit dosage forms.
- the compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those familiar to those skilled in the art. Equivalent alternatives. Preferred implementations include, but are not limited to, the examples of this application.
- the compounds of the present application can be prepared according to the routes described in Scheme 1 or Scheme 2.
- Each product obtained by the reaction in Scheme 1 or Scheme 2 can be obtained by traditional separation techniques, which include, but are not limited to, filtration, distillation, crystallization, and chromatographic separation.
- the starting materials can be synthesized by themselves or purchased from commercial organizations (such as, but not limited to, Adrich or Sigma). These materials can be characterized using conventional means, such as physical constants and spectral data.
- the compounds described in this application can be synthesized to obtain a single isomer or a mixture of isomers.
- reaction bottles are equipped with a rubber septum to allow the substrate and reagents to be added via a syringe; glassware is dried and / Or heat to dry.
- Nuclear magnetic data ( 1 H NMR) was run at 400 MHz using a Varian device.
- the solvents used in NMR data are CDCl 3 , CD 3 OD, D 2 O, DMSO-d 6 and the like, based on tetramethylsilane (0.00ppm) or based on residual solvents (CDCl 3 : 7.26ppm; CD 3 OD : 3.31 ppm; D 2 O: 4.79 ppm; DMSO-d 6 : 2.50 ppm).
- Example 1 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- [4- (methylsulfonyl) phenoxy] phenyl ⁇ -N-ethyl Methyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- Step B 3-bromo-4- [4- (methylsulfonyl) phenoxy] aniline
- Step D N- ⁇ 3-Bromo-4- [4- (methylsulfonyl) phenoxy] phenyl ⁇ -S, S-dimethylsulfonylimide
- Step E 4-Bromo-7-methoxy-1-p-toluenesulfonyl-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid n-butyl ester
- Step F 4-Bromo-7-oxo-1-p-toluenesulfonyl-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid n-butyl ester
- Step G 4-Bromo-6-methyl-7-oxo-1-p-toluenesulfonyl-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid n-butyl ester
- Step H 4-Bromo-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- Step I N-ethyl-6-methyl-7-oxo-4- (4,4,55-tetramethyl-1,3,2-dioxorane-2-yl)- 6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- Step J 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- [4- (methylsulfonyl) phenoxy] phenyl ⁇ -N-ethyl Methyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- N- ⁇ 3-bromo-4- [4- (methylsulfonyl) phenoxy] phenyl ⁇ -S, S- was sequentially added to an 80% dioxane aqueous solution (3 mL).
- Step A 4- ⁇ 2-Bromo-4- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ phenoxy ⁇ -3-fluorobenzonitrile
- Step B 4-bromo-6-methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step C 6-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxorane-2-yl) -1,6-dihydro-7H -Pyrrolo [2,3-c] pyridin-7-one
- Step D 4- ⁇ 4- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (6-methyl-7-oxo-6,7-dihydro-1H- Pyrrolo [2,3-c] pyridin-4-yl) phenoxy ⁇ -3-fluorobenzonitrile
- Step A 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- [4- (methylsulfonyl) phenoxy] phenyl ⁇ -6-form -L-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- N- ⁇ 3-bromo-4- [4- (methylsulfonyl) phenoxy] phenyl ⁇ -S, S- was sequentially added to an 80% dioxane aqueous solution (3 mL).
- Dimethylsulfonylimide (40mg), 6-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxorane-2-yl)- 1-Toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-C] pyridin-7-one (61mg, reference J. Med. Chem.
- Step B 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- [4- (methylsulfonyl) phenoxy] phenyl ⁇ -6-formaldehyde -1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one
- Step A N- [5-Bromo-6- (2,4-difluorophenoxy) pyridin-3-yl] -S, S-dimethylsulfonylimide
- Step B 4- ⁇ 2- (2,4-difluorophenoxy) -5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-3-yl ⁇ -6 -Methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step C 4- ⁇ 2- (2,4-difluorophenoxy) -5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-3-yl ⁇ -6 -Methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step C 4- (2,4-difluorophenoxy) -3- (4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl) aniline
- Step D 4- [5-Amino-2- (2,4-difluorophenoxy) phenyl] -6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step E 4- (2- (2,4-difluorophenoxy) -5-iodobenzene) -6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [ 2,3-c] pyridine-7-one
- Step F 4- ⁇ 2- (2,4-difluorophenoxy) -5- ⁇ [dimethyl (oxy) - ⁇ 6 -sulfinyl] amino ⁇ phenyl ⁇ -6-methyl- 1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step G 4- ⁇ 2- (2,4-difluorophenoxy) -5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ phenyl ⁇ -6-methyl- 1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one
- Step A N- ⁇ 3-Bromo-4- [4- (2-chloro-6-methylphenoxy] phenyl ⁇ -S, S-dimethylsulfonylimide
- Step B 4- ⁇ 2- (2-Chloro-6-methylphenoxy) -5- [dimethyl (oxo) - ⁇ 6 -sulfinyl] aminophenyl ⁇ -6-methyl- 1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one
- N- ⁇ 3-bromo-4- [4- (2-chloro-6-methylbenzene) was sequentially added to a mixed solvent of 1,4-dioxane (10 mL) and water (1 mL).
- Example 7 4- ⁇ 2- (2-Chloro-6-methylphenoxy) -5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ phenyl ⁇ -N-ethyl Methyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- N- ⁇ 3-bromo-4- [4- (2-chloro-6-methylbenzene) was sequentially added to a mixed solvent of 1,4-dioxane (10 mL) and water (1 mL).
- Example 8 4- ⁇ 2- (2,4-difluorophenyl) amino-5- [dimethyl (oxo) - ⁇ 6 -sulfinyl] aminophenyl ⁇ -6-methyl-1, 6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- step A of Reference Example 1 was used to obtain the product (2.5 g).
- Step B 2-bromo-4-nitro-N- (2,4-difluorophenyl) -N-tert-butoxycarbonylaniline
- Step C 2-bromo-4-amino-N '-(2,4-difluorophenyl) -N'-tert-butoxycarbonylaniline
- Step D 2-Bromo-4-iodo-N- (2,4-difluorophenyl) -N-tert-butoxycarbonylaniline
- Step E N- ⁇ 3-Bromo-4- [N '-(2,4-difluorophenyl) -N'-tert-butoxycarbonylamino] phenyl ⁇ -S, S-dimethylsulfonimide amine
- Step F 4- ⁇ 2- [N- (2,4-difluorophenyl) -N-tert-butoxycarbonylamino] -5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] Amino ⁇ phenyl ⁇ -6-methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step G 4- ⁇ 2- (2,4-difluorophenyl) amino-5- [dimethyl (oxo) - ⁇ 6 -sulfinyl] aminophenyl ⁇ -6-methyl-1, 6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step A N- ⁇ 3-bromo-4-[(2-methylpyridin-3-yl) oxy] phenyl ⁇ -S, S-dimethylsulfonylimide
- Step B 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2-[(2-methyl-pyridin-3-yl) oxy] phenyl ⁇ - 6-methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Example 10 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- Step B 2- (2-Bromo-4-nitrophenoxy) -5-fluoro-1,3-dimethylbenzene
- Step D 2- (2-Bromo-4-iodophenoxy) -5-fluoro-1,3-dimethylbenzene
- Step E N- [3-Bromo-4- (4-fluoro-2,6-dimethylphenoxy) phenyl] -S, S-dimethylsulfonylimide
- Step F 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- N- [3-bromo-4- (4-fluoro-2,6-dimethylphenoxy) phenyl] -S was sequentially added to an 80% aqueous solution of dioxane (10 mL).
- S-Dimethylsulfonylimide 25mg
- N-ethyl-6-methyl-7-oxo-4- (4,4,5,5-tetramethyl-1,3,2- Dioxorane-2-yl) -6,7-dihydro-1H-pyrrolo [2,3-c]
- pyridine-2-carboxamide 25 mg
- potassium phosphate 25 mg
- PdCl 2 dppf
- Example 11 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step A 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- N- [3-bromo-4- (4-fluoro-2,6-dimethylphenoxy) phenyl] -S was sequentially added to an 80% aqueous solution of dioxane (10 mL).
- S-dimethylsulfimide 26mg
- -1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one 17. mg
- potassium phosphate 28 mg
- PdCl 2 (dppf) 5 mg
- Step B 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Example 12 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2-[(tetrahydrofuran-3-yl) methoxy] phenyl ⁇ -6-methyl -1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one
- Step D N- ⁇ 3-Bromo-4-[(tetrahydrofuran-3-yl) methoxy] phenyl ⁇ -S, S-dimethylsulfonylimide
- Step E 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2-[(tetrahydrofuran-3-yl) methoxy] phenyl ⁇ -6-methyl -1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- N- ⁇ 3-bromo-4-[(tetrahydrofuran-3-yl) methoxy] phenyl ⁇ -S, S-di was sequentially added to an 80% dioxane aqueous solution (10 mL).
- Step F 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2-[(tetrahydrofuran-3-yl) methoxy] phenyl ⁇ -6-methyl -1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one
- Example 13 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid
- Step A 6-methyl-7-oxo-4- (4,4,5,5-tetramethyl-1,3,2-dioxorane-2-yl) -1-pair Tosyl-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid butyl ester
- Step B 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ -6-methyl-7-oxo-1-p-toluenesulfonyl-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid butyl ester
- N- [3-bromo-4- (4-fluoro-2,6-dimethylphenoxy) phenyl] -S was sequentially added to an 80% aqueous solution of dioxane (10 mL).
- S-Dimethylsulfonylimide (83mg), 6-methyl-7-oxo-4- (4,4,5,5-tetramethyl-1,3,2-dioxorane heterocyclic ring
- Pentane-2-yl -1-p-toluenesulfonyl-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid butyl ester (160 mg), potassium phosphate (93 mg) And PdCl 2 (dppf) (16 mg), followed by heating to 80 ° C.
- Step C 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid
- Example 14 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid ethyl ester
- Step B 2-bromo-1- (2,4-difluorophenoxy) -4-iodobenzene
- Step C 1- ⁇ [3-Bromo-4- (2,4-difluorophenoxy) phenyl] imino ⁇ tetrahydro-1H-1 ⁇ 6 -thiophene-1-oxide
- Step D 4- ⁇ 2- (2,4-difluorophenoxy) -5-[(1-oxytetrahydro-1 ⁇ 6 -thiophen-1-ylidene) amino] phenyl ⁇ -6-methyl -1-p-toluenesulfonyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step E 4- ⁇ 2- (2,4-difluorophenoxy) -5-[(1-oxytetrahydro-1 ⁇ 6 -thiophen-1-ylidene) amino] phenyl ⁇ -6-methyl -1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one
- Example 16 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) pyridine-3- ⁇ -N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- Step A N- [5-Bromo-6- (4-fluoro-2,6-dimethylphenoxy) pyridin-3-yl] -S, S-dimethylsulfonylimide
- Step B 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) pyridine-3- ⁇ -N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- N- [5-bromo-6- (4-fluoro-2,6-dimethylphenoxy) pyridin-3-yl was sequentially added to an 80% dioxane aqueous solution (10 mL).
- -S S-dimethylsulfonylimide (50mg), N-ethyl-6-methyl-7-oxo-4- (4,4,5,5-tetramethyl-1,3 , 2-dioxorane-2-yl) -6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide (54 mg), potassium phosphate (55 mg), and PdCl 2 (dppf) (10 mg), followed by heating to 80 ° C.
- Step A 1- (2-bromo-4-nitrophenyl) -3-methylpyridine-4 (1H) -one
- Step B 1- (2-bromo-4-aminophenyl) -3-methylpyridine-4 (1H) -one
- Step C 1- (2-bromo-4-iodophenyl) -3-methylpyridine-4 (1H) -one
- Step D N- ⁇ 3-Bromo-4- [3-methyl-4-oxopyridine-1 (4H) -yl] phenyl ⁇ -S, S-dimethylsulfonylimide
- Step E 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- [3-methyl-4-oxopyridine-1 (4H) -yl] benzene ⁇ -6-methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridin-7-one
- Example 18 4- ⁇ 3- (2,4-difluorophenoxy) -6- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-2-yl ⁇ -6 -Methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step C 5- (2,4-difluorophenoxy) -2- (ethoxycarbonyl) pyridine 1-oxide
- Step F [6-Bromo-5- (2,4-difluorophenoxy) pyridin-2-yl] carbamic acid tert-butyl ester
- Step G 6-bromo-5- (2,4-difluorophenoxy) pyridin-2-amine
- Step H 2-bromo-3- (2,4-difluorophenoxy) -6-iodopyridine
- Step I ((6-Bromo-5- (2,4-difluorophenoxy) pyridin-2-yl) imino) dimethyl- ⁇ 6 -sulfonimide
- Step J 4-Bromo-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester
- Step K 6-Methyl-7-oxo-4- (4,4,5,5-tetramethyl-1,3,2-dioxorane-2-yl) -6,7 -Dihydro-1H-pyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester
- Step L 4- ⁇ 3- (2,4-difluorophenoxy) -6- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-2-yl ⁇ -6 -Methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester
- Step M 4- ⁇ 3- (2,4-difluorophenoxy) -6- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-2-yl ⁇ -6 -Methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- the reaction was quenched with a saturated aqueous citric acid solution (15 mL), sodium chloride solid was added to saturation, and extracted with ethyl acetate 3 times. The extracts were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to obtain a crude product (0.50 g), which can be directly used in the next part of the reaction.
- Step E [4-Bromo-5- (2,4-difluorophenoxy) pyridin-2-yl] carbamic acid tert-butyl ester
- Step F 4-Bromo-5- (2,4-difluorophenoxy) pyridine-2-amine
- Step G 4-bromo-5- (2,4-difluorophenoxy) -2-iodopyridine
- Step H ((4-bromo-5- (2,4-difluorophenoxy) pyridin-2-yl) imino) dimethyl- ⁇ 6 -sulfonimide
- Step I 4- ⁇ 5- (2,4-difluorophenoxy) -2- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-4-yl ⁇ -6 -Methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester
- Step J 4- ⁇ 5- (2,4-difluorophenoxy) -2- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-4-yl ⁇ -6 -Methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Step A 3-bromo-2- (2-chloro-6-methylphenoxy) -5-nitropyridine
- Step B ((5-bromo-6- (2-chloro-6-methylphenoxy) pyridin-3-yl) imino) dimethyl- ⁇ 6 -sulfonimide
- Step C 4- ⁇ 2- (2-Chloro-6-methylphenoxy) -5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-3-yl ⁇ -6-methyl-1,6-dihydro-7H-pyrrolo [2,3-c] pyridine-7-one
- Example 21 4- ⁇ 2- (2-Chloro-6-methylphenoxy) -5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -pyridin-3-yl ⁇ -N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- Example 22 4- ⁇ 5- ⁇ [Dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-7-oxo-N- (2,2,2-trifluoroethyl) -6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- Step A 4-Bromo-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxylic acid
- Step B 4-bromo-6-methyl-7-oxo-N- (2,2,2-trifluoroethyl) -6,7-dihydro-1H-pyrrolo [2,3-c] Pyridine-2-carboxamide
- Step D 4- ⁇ 5- ⁇ [dimethyl (oxo) - ⁇ 6 -sulfinyl] amino ⁇ -2- (4-fluoro-2,6-dimethylphenoxy) phenyl ⁇ - 6-methyl-7-oxo-N- (2,2,2-trifluoroethyl) -6,7-dihydro-1H-pyrrolo [2,3-c] pyridine-2-carboxamide
- the IC 50 value of the compound for inhibiting the BRD4 (BD2) enzyme-binding reaction is performed by a homogeneous time-resolved fluorescence (HTRF) method.
- Compounds were diluted 5-fold (total 7 concentrations) with 100% DMSO starting from 1 mM, and 2 ⁇ L of each compound was added to 18 ⁇ L of reaction buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM DTT, 0.005% Tween 20 and 100 ⁇ g / mL BSA) were diluted. After mixing, 2 ⁇ L of the compound at each concentration was added to 48 ⁇ L of the above reaction buffer for further dilution and mixing (final compound DMSO concentration was 0.1%).
- the IC 50 value of the compound for inhibiting the BRD4 (BD1) enzyme-binding reaction is performed by a homogeneous time-resolved fluorescence (HTRF) method.
- HTRF time-resolved fluorescence
- Human acute lymphoblastic leukemia cell line cells MV4-11 use PRIM1640 medium plus 10% fetal bovine serum (FBS, purchased from Biological Industries, BI) and 1% penicillin / streptomycin dual antibody (P / S, purchased from Life Techonology). The culture conditions were 37 ° C and 5% CO 2 . The day before compound detection, MV4-11 cells were plated in 96-well plates (purchased from Corning) at a concentration of 8000 cells / 195 ⁇ L / well. After 24 hours, the compounds were diluted 4 times (total 9 concentrations) with 100% DMSO starting from 10 mM, and then 2 ⁇ L of each compound was added to 48 ⁇ L of PRIM1640 medium for dilution.
- FBS fetal bovine serum
- P / S penicillin / streptomycin dual antibody
- Kasumi-1 cells use PRIM1640 medium plus 20% fetal bovine serum (FBS, purchased from Biological Industries, BI) and 1% penicillin / streptomycin dual antibody (P / S, purchased at Life Techonology). The culture conditions were 37 ° C and 5% CO 2 . The day before compound detection, Kasumi-1 cells were plated in a 96-well plate (purchased from Corning) at a concentration of 5000 cells / 195 ⁇ L / well. After 24 hours, the compounds were diluted 4 times (total 9 concentrations) with 100% DMSO starting from 10 mM, and then 2 ⁇ L of each compound was added to 48 ⁇ L of PRIM1640 medium for dilution.
- FBS fetal bovine serum
- P / S penicillin / streptomycin dual antibody
- Animal pharmacokinetic experiments used 3 healthy adult male rats from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.
- the compound was suspended in 2% absolute ethanol, 5% Tween 80, 20% polyethylene glycol 400, 73% (5% hydroxypropyl methyl cellulose in water) (V / V / V / V), The concentration was 1 mg / mL, the administration volume was 5 mL / kg, and a single intragastric administration was performed at a dose of 5 mg / kg. Animals were fasted overnight before the experiment, and the fasting time ranged from 10 hours to 4 hours after dosing. Blood was collected at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after administration.
- the animals were anesthetized with isoflurane, and about 0.4 mL of whole blood was collected from the orbital venous plexus with a glass blood collection tube and placed in a heparin anticoagulation tube. The samples were centrifuged at 4 ° C and 4200 rpm for 5 minutes. Store at -80 ° C until analysis. Plasma sample analysis The acetonitrile protein precipitation method was used to extract test compounds and internal standards (warfarin or propranolol) in rat plasma, and the extracts were analyzed by LC / MS / MS.
- the measured plasma concentration-time data of individual animals were analyzed using a non-compartment model of WinNonlin (version 5.2.1; Pharsight) software, and the pharmacokinetic parameters shown in Table 3 below were obtained: the maximum (peak) plasma drug Concentration C max ; peak time T max ; half-life T 1/2 and the area under the plasma concentration-time curve extrapolated to infinite time AUC 0-inf .
Abstract
Description
Claims (20)
- 式I所示的化合物或其药学上可接受的盐,其中,R 1选自H、C 1-C 3烷基或C 1-C 3酰基,所述C 1-C 3烷基或C 1-C 3酰基任选地被一个或多个卤素取代;Y选自O、S或NR Y,所述R Y选自H、C 1-C 3烷基或C 1-C 3酰基,所述C 1-C 3烷基或C 1-C 3酰基任选地被一个或多个卤素取代;X 1选自N或CR X1,所述R X1选自H、C 1-C 6烷基、卤素或C 1-C 6卤代烷基;X 2选自N或CR X2,X 3选自N或CR X3,所述R X2、和R X3各自独立地选自H、卤素、C 1-C 6烷基、C 2-C 6烯基、C 2-C 6炔基、-C(O)OR a、-C(O)NR bR c、-C(O)R d、-S(O) 2R e或-S(O) 2NR bR c,所述C 1-C 6烷基、C 2-C 6烯基或C 2-C 6炔基任选地被一个或多个卤素、羟基、氨基、硝基或氰基取代;Z 1选自N或CR Z1,Z 2选自N或CR Z2,Z 3选自N或CR Z3,所述R Z1、R Z2、和R Z3各自独立地选自H、C 1-C 6烷基、C 2-C 6烯基、C 2-C 6炔基、卤素、氰基或硝基,所述C 1-C 6烷基、C 2-C 6烯基或C 2-C 6炔基任选地被一个或多个卤素、羟基、氨基、硝基或氰基取代;R 2和R 3各自独立地选自卤素、羟基、C 1-C 6烷基、C 2-C 6烯基、C 2-C 6炔基、C 1-C 6烷氧基、C 1-C 6烷氨基或(C 1-C 6烷基) 2氨基,所述C 1-C 6烷基、C 2-C 6烯基、C 2-C 6炔基、C 1-C 6烷氧基、C 1-C 6烷氨基或(C 1-C 6烷基) 2氨基任选地被一个或多个卤素、羟基、氨基、硝基或氰基取代;或者,R 2和R 3相连接并与相邻的S原子一起形成3元~8元杂环烷基,所述3元~8元杂环烷基除R 2和R 3共同相连的S原子外,任选地含有1~3个选自N、O或S的杂原子;所述3元~8元杂环烷基的环碳原子任选地被一个或多个卤素、羟基、氨基、硝基、氰基、C 1-C 6烷基、C 1-C 6卤代烷基、C 1-C 6烷氧基、C 1-C 6烷氨基或(C 1-C 6烷基) 2氨基取代,或被一个或多个氧代;L选自单键、-O-、-NH-、-(C 1-C 3烷基)-O-、-(C 1-C 3烷基)-NH-或-C 1-C 3烷基-;R 4选自C 6-C 10芳基、C 3-C 10环烯基、C 3-C 10环烷基、3元~10元杂芳基、3元~10元杂环烯基或3元~10元杂环烷基,所述3元~10元杂芳基、3元~10元杂环烯基或3元~10元杂环烷基各自独立地含有1~3个选自N、O或S的杂原子;所述R 4任选地被一个或多个卤素、羟基、氨基、硝基、氰基、C 1-C 6烷基、C 1-C 6卤代烷基、C 1-C 6烷氧基、C 1-C 6烷氨基、(C 1-C 6烷基) 2氨基、-C(O)OR a、-C(O)NR bR c、-C(O)R d、-S(O) 2R e、-NHS(O) 2R e或-S(O) 2NR bR c取代,或被一个或多个氧代;所述R a、R b、R c、R d和R e各自独立地选自H、C 1-C 6烷基或C 1-C 6卤代烷基。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述R 1选自H或C 1-C 3烷基,所述C 1-C 3烷基任选地被一个或多个F、Cl或Br取代。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述Y选自NR Y,所述R Y选自H、C 1-C 3烷基,所述C 1-C 3烷基任选地被一个或多个F、Cl或Br取代。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述X 1选自CR X1,所述R X1选自H、C 1-C 4烷基、F、Cl、Br或被F、Cl或Br取代的C 1-C 4烷基。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述X 2选自CR X2,所述R X2选自H、-C(O)OR a或-C(O)NR bR c。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述X 3选自CR X3,所述R X3选自H或C 1-C 4烷基,所述C 1-C 4烷基任选地被一个或多个F、Cl、Br、羟基、氨基、硝基或氰基取代。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述Z 1选自N或CR Z1,所述 R Z1选自H、C 1-C 4烷基、C 2-C 4烯基、C 2-C 4炔基、卤素、氰基或硝基,所述C 1-C 4烷基、C 2-C 4烯基或C 2-C 4炔基任选地被一个或多个卤素、羟基、氨基、硝基或氰基取代。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述Z 2选自CR Z2,所述R Z2选自H、C 1-C 4烷基、C 2-C 4烯基、C 2-C 4炔基、卤素、氰基或硝基,所述C 1-C 4烷基、C 2-C 4烯基或C 2-C 4炔基任选地被一个或多个F、Cl、Br、羟基、氨基、硝基或氰基取代。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述Z 3选自N或CR Z3,所述R Z3选自H、C 1-C 4烷基、C 2-C 4烯基、C 2-C 4炔基、卤素、氰基或硝基,所述C 1-C 4烷基、C 2-C 4烯基或C 2-C 4炔基任选地被一个或多个F、Cl、Br、羟基、氨基、硝基或氰基取代。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述R 2和R 3各自独立地选自C 1-C 4烷基、C 2-C 4烯基、C 2-C 4炔基、C 1-C 4烷氧基、C 1-C 4烷氨基或(C 1-C 4烷基) 2氨基,所述C 1-C 4烷基、C 2-C 4烯基、C 2-C 4炔基、C 1-C 4烷氧基、C 1-C 4烷氨基或(C 1-C 4烷基) 2氨基任选地被一个或多个F、Cl、Br、羟基、氨基、硝基或氰基取代;或者R 2和R 3相连接并与相邻的S原子一起形成4元~6元杂环烷基,所述4元~6元杂环烷基除R 2和R 3共同相连的S原子外,任选地含有1~3个选自N、O或S的杂原子;所述4元~6元杂环烷基的环碳原子任选地被一个或多个F、Cl、Br、羟基、氨基、硝基、氰基、C 1-C 4烷基、C 1-C 4卤代烷基、C 1-C 4烷氧基、C 1-C 4烷氨基或(C 1-C 4烷基) 2氨基取代,或被一个或多个氧代。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述L选自单键、-O-、-NH-或-(C 1-C 3烷基)-O-。
- 如权利要求1所述的式I所示的化合物或其药学上可接受的盐,所述R 4选自苯基、萘基、哌啶基、吡啶基、咪唑基、吡唑基、吡嗪基、哌嗪基、噻吩基、呋喃基、噻唑基、异噻唑基、噁唑基、异噁唑基、1,4-二氢吡啶基或四氢呋喃基;所述R 4任选地被一个或多个F、Cl、Br、氰基、甲基、乙基、丙基、丁基、三氟甲基、甲氧基、乙氧基、丙氧基、甲基氨基、乙基氨基、丙基氨基、(甲基) 2氨基、(乙基) 2氨基、(丙基) 2氨基、-C(O)OH、-C(O)OCH 3、-C(O)OC 2H 5、-C(O)NH 2、-C(O)NHCH 3、-C(O)NHC 2H 5、-C(O)N(CH 3) 2、-C(O)N(C 2H 5) 2、乙酰基、-S(O) 2CH 3、-S(O) 2C 2H 5、-NHS(O) 2CH 3、-NHS(O) 2C 2H 5、-S(O) 2NH 2、-S(O) 2NHCH 3、-S(O) 2NHC 2H 5、-S(O) 2N(CH 3) 2、-S(O) 2N(C 2H 5) 2取代,或被一个或多个氧代。
- 药物组合物,其包含如权利要求1所述的式I化合物或其药学上可接受的盐。
- 治疗哺乳动物由BET蛋白介导的疾病的方法,包括对需要该治疗的哺乳动物,给予治疗有效量的如权利要求1所述的式I化合物或其药学上可接受的盐、或如权利要求18所述的药物组合物。
- 如权利要求19所述的治疗哺乳动物由BET蛋白介导的疾病的方法,所述由BET蛋白介导的疾病选自癌症。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3106733A CA3106733A1 (en) | 2018-07-25 | 2019-07-25 | Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof |
CN201980047285.5A CN112424200B (zh) | 2018-07-25 | 2019-07-25 | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 |
CN202211301551.2A CN115716827A (zh) | 2018-07-25 | 2019-07-25 | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 |
JP2021527274A JP2021533186A (ja) | 2018-07-25 | 2019-07-25 | ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途 |
US17/262,053 US20210300923A1 (en) | 2018-07-25 | 2019-07-25 | Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof |
KR1020217005605A KR20210038921A (ko) | 2018-07-25 | 2019-07-25 | 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도 |
AU2019312393A AU2019312393B2 (en) | 2018-07-25 | 2019-07-25 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof |
EP19842279.2A EP3828183A4 (en) | 2018-07-25 | 2019-07-25 | SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810825047 | 2018-07-25 | ||
CN201810825047.X | 2018-07-25 | ||
CN201910410273 | 2019-05-17 | ||
CN201910410273.6 | 2019-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020020288A1 true WO2020020288A1 (zh) | 2020-01-30 |
Family
ID=69180818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/097692 WO2020020288A1 (zh) | 2018-07-25 | 2019-07-25 | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210300923A1 (zh) |
EP (1) | EP3828183A4 (zh) |
JP (1) | JP2021533186A (zh) |
KR (1) | KR20210038921A (zh) |
CN (2) | CN112424200B (zh) |
AU (1) | AU2019312393B2 (zh) |
CA (1) | CA3106733A1 (zh) |
WO (1) | WO2020020288A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020187123A1 (zh) * | 2019-03-17 | 2020-09-24 | 上海凌达生物医药有限公司 | 一类吡咯酰胺并吡啶酮类化合物、制备方法和用途 |
WO2021143922A1 (zh) * | 2020-01-19 | 2021-07-22 | 正大天晴药业集团股份有限公司 | 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法 |
US11192900B2 (en) | 2018-10-30 | 2021-12-07 | Nuvation Bio Inc. | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors |
CN114286818A (zh) * | 2019-07-02 | 2022-04-05 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
WO2022090699A1 (en) * | 2020-10-26 | 2022-05-05 | In4Derm Limited | Pyridone-containing compounds as bromodomain protein inhibitors |
WO2022237875A1 (zh) * | 2021-05-12 | 2022-11-17 | 正大天晴药业集团股份有限公司 | 含有亚磺酰亚胺基的atr抑制剂化合物 |
WO2022242697A1 (zh) * | 2021-05-19 | 2022-11-24 | 南京药石科技股份有限公司 | Tyk2选择性抑制剂及其用途 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
WO2009158404A1 (en) | 2008-06-26 | 2009-12-30 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
WO2011143669A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
WO2011161031A1 (en) | 2010-06-22 | 2011-12-29 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
WO2012075383A2 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013097601A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Bromodomain inhibitors |
US20150246923A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
WO2017063959A1 (de) * | 2015-10-15 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren |
WO2017177955A1 (en) | 2016-04-15 | 2017-10-19 | Abbvie Inc. | Bromodomain inhibitors |
CN108069958A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
WO2018130174A1 (zh) * | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015017963A (es) * | 2013-06-28 | 2016-11-10 | Abbvie Inc | Inhibidores de bromodominio. |
WO2021003310A1 (en) * | 2019-07-02 | 2021-01-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
-
2019
- 2019-07-25 JP JP2021527274A patent/JP2021533186A/ja active Pending
- 2019-07-25 AU AU2019312393A patent/AU2019312393B2/en active Active
- 2019-07-25 CN CN201980047285.5A patent/CN112424200B/zh active Active
- 2019-07-25 US US17/262,053 patent/US20210300923A1/en active Pending
- 2019-07-25 CA CA3106733A patent/CA3106733A1/en active Pending
- 2019-07-25 CN CN202211301551.2A patent/CN115716827A/zh active Pending
- 2019-07-25 EP EP19842279.2A patent/EP3828183A4/en active Pending
- 2019-07-25 KR KR1020217005605A patent/KR20210038921A/ko unknown
- 2019-07-25 WO PCT/CN2019/097692 patent/WO2020020288A1/zh active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
WO2009158404A1 (en) | 2008-06-26 | 2009-12-30 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
WO2011143669A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
WO2011161031A1 (en) | 2010-06-22 | 2011-12-29 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
WO2012075383A2 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2013097601A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Bromodomain inhibitors |
CN104136435A (zh) * | 2011-12-30 | 2014-11-05 | 艾伯维公司 | 溴结构域抑制剂 |
US20150246923A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
WO2017063959A1 (de) * | 2015-10-15 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren |
WO2017177955A1 (en) | 2016-04-15 | 2017-10-19 | Abbvie Inc. | Bromodomain inhibitors |
CN108069958A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
WO2018130174A1 (zh) * | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
Non-Patent Citations (9)
Title |
---|
BELKINA A CDENIS G V, NATURE REVIEWS CANCER, vol. 12, no. 7, 2012, pages 465 - 477 |
DENIS G V., DISCOVERY MEDICINE, vol. 10, no. 55, 2010, pages 489 |
HUANG BYANG X DZHOU M M ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 29, no. 5, 2009, pages 1375 - 1387 |
J. MED. CHEM., vol. 60, 2017, pages 8369 - 8384 |
MATZUK M MMCKEOWN M RFILIPPAKOPOULOS P ET AL., CELL, vol. 150, no. 4, 2012, pages 673 - 684 |
MED. CHEM., vol. 60, 2017, pages 8369 - 8384 |
See also references of EP3828183A4 |
ZHANG GLIU RZHONG Y ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 34, 2012, pages 28840 - 28851 |
ZUBER JSHI JWANG E ET AL., NATURE, vol. 478, no. 7370, 2011, pages 524 - 528 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11192900B2 (en) | 2018-10-30 | 2021-12-07 | Nuvation Bio Inc. | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors |
WO2020187123A1 (zh) * | 2019-03-17 | 2020-09-24 | 上海凌达生物医药有限公司 | 一类吡咯酰胺并吡啶酮类化合物、制备方法和用途 |
CN111704610A (zh) * | 2019-03-17 | 2020-09-25 | 上海凌达生物医药有限公司 | 一类吡咯酰胺并吡啶酮类化合物、制备方法和用途 |
CN114286818A (zh) * | 2019-07-02 | 2022-04-05 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
US11584756B2 (en) | 2019-07-02 | 2023-02-21 | Nuvation Bio Inc. | Heterocyclic compounds as BET inhibitors |
WO2021143922A1 (zh) * | 2020-01-19 | 2021-07-22 | 正大天晴药业集团股份有限公司 | 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法 |
EP4092027A4 (en) * | 2020-01-19 | 2024-02-14 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | CRYSTAL FORM AND SALT FORM OF A BROMODOMAIN PROTEIN INHIBITOR AND METHOD FOR THE PRODUCTION THEREOF |
WO2022090699A1 (en) * | 2020-10-26 | 2022-05-05 | In4Derm Limited | Pyridone-containing compounds as bromodomain protein inhibitors |
WO2022237875A1 (zh) * | 2021-05-12 | 2022-11-17 | 正大天晴药业集团股份有限公司 | 含有亚磺酰亚胺基的atr抑制剂化合物 |
WO2022242697A1 (zh) * | 2021-05-19 | 2022-11-24 | 南京药石科技股份有限公司 | Tyk2选择性抑制剂及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CA3106733A1 (en) | 2020-01-30 |
EP3828183A4 (en) | 2022-03-09 |
CN112424200B (zh) | 2022-09-20 |
EP3828183A1 (en) | 2021-06-02 |
AU2019312393A1 (en) | 2021-03-18 |
AU2019312393B2 (en) | 2022-12-22 |
CN112424200A (zh) | 2021-02-26 |
US20210300923A1 (en) | 2021-09-30 |
CN115716827A (zh) | 2023-02-28 |
JP2021533186A (ja) | 2021-12-02 |
KR20210038921A (ko) | 2021-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020020288A1 (zh) | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 | |
JP7399299B2 (ja) | Glp-1r調節化合物 | |
US9980952B2 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
CN110452216B (zh) | 抗纤维化吡啶酮类 | |
KR102022716B1 (ko) | 하이드라지드 함유 핵 수송 조절인자 및 이의 용도 | |
TWI771630B (zh) | 溴結構域(bromodomain)抑制劑 | |
WO2019101086A1 (zh) | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 | |
WO2020011246A1 (zh) | 含苯环的化合物、其制备方法及应用 | |
TW201443023A (zh) | 作爲rock抑制劑之酞□酮及異喹啉酮 | |
JP2010526078A (ja) | Wntシグナル伝達のピラゾールインヒビター | |
KR102470130B1 (ko) | 아폽토시스 억제제 | |
JP2001139550A (ja) | アミド化合物の新規用途 | |
WO2019223629A1 (zh) | 苯基取代的二氢萘啶类化合物及其用途 | |
TW202041498A (zh) | 抑制pge2/ep4信號傳導的化合物、其製備方法及其在醫藥上的應用 | |
JP2021506859A (ja) | Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン | |
JP2022532719A (ja) | Acss2阻害剤およびその使用方法 | |
CN110612296A (zh) | 作为pge2受体调节剂的苯基衍生物 | |
TW202128644A (zh) | 作為lpa受體拮抗劑之***胺基甲酸酯吡啶基磺醯胺及其用途 | |
WO2019089670A1 (en) | Alkene compounds as farnesoid x receptor modulators | |
CN109415384B (zh) | 稠合杂环化合物 | |
CN109641909B (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
KR102492715B1 (ko) | 모노시클릭 헤테로아릴 치환된 화합물 | |
CN116457346A (zh) | 作为新型二酰基甘油酯o-酰基转移酶2抑制剂的吲哚酮衍生物的制备 | |
BR112021010473A2 (pt) | Composto de inibição de dock1 e uso | |
CN115427407A (zh) | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19842279 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3106733 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021527274 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217005605 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019842279 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2019842279 Country of ref document: EP Effective date: 20210225 |
|
ENP | Entry into the national phase |
Ref document number: 2019312393 Country of ref document: AU Date of ref document: 20190725 Kind code of ref document: A |